ASTRAZENECA ORD USD0.25

Symbol: AZN

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Overview

Core Data
Latest Dividend Information

Ex-Dividend Date 25 Feb 2021
Pay Date 29 Mar 2021
Total Dividends - Year to Date216
Dividend Yield (%)2.8575

Historical Data & Ratios

Avg Volume Over 10 Days2.2960
Market Cap (M)99019.8800
Price/Earnings (PE)51.4288
Earnings Per Share146.98
Revenue Per Share13.7439
Return on Equity %10.4317

1 Month Performance Chart

One Month Chart

Broker View
Data shown is based on the past 75 days of broker views.

ActionBrokers

Strong Buy18

Buy2

Neutral3

Sell0

Strong Sell1

Brokers 18 2 3 0 1
Consensus

ConsensusStrong Buy

Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here
0.35%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included
N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs
N/A N/A
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Charts

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Company

      Business Summary

      AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

      Financial Summary

      BRIEF: For the nine months ended 30 September 2020,AstraZeneca plc revenues increased 8% to $19.21B. Netincome increased from $1.02B to $2.18B. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net income benefitedfrom Finance expense decrease of 9% to $985M (expense), SGARestructuring Charges/Provisions decrease of 54% to $67M(expense).

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/12/2019

      31/12/2018

      31/12/2017

      31/12/2016

      31/12/2015

      31/12/2014

      Total Revenue 24,384.00 22,090.00 22,465.00 23,002.00 24,708.00 26,547.00
      Gross profit 19,589.00 17,877.00 18,328.00 19,006.00 20,220.00 20,958.00
      Operating Profit/Loss 2,924.00 3,387.00 3,677.00 4,902.00 4,114.00 2,137.00
      Profit Before Tax 1,548.00 1,993.00 2,227.00 3,552.00 3,069.00 1,246.00
      Profit After Tax 1,227.00 2,050.00 2,252.00 3,406.00 2,826.00 1,235.00
      Equity Holders of Parent Company 1,335.00 2,155.00 3,001.00 3,499.00 2,825.00 1,233.00
      Minority Interest 1,577.00 1,681.00 1,815.00 1,908.00 18.00 17.00


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/12/2019

      31/12/2018

      31/12/2017

      31/12/2016

      31/12/2015

      31/12/2014

      Total Non-Current Assets 45,814.00 45,060.00 50,204.00 49,264.00 44,117.00 41,898.00
      Total Current Assets 15,563.00 15,591.00 13,150.00 13,262.00 16,007.00 16,697.00
      Total Assets 61,377.00 60,651.00 63,354.00 62,526.00 60,124.00 58,595.00
      Total Liabilities 46,781.00 46,607.00 46,712.00 45,857.00 41,615.00 38,949.00
      Total Net Assets 14,596.00 14,044.00 16,642.00 16,669.00 18,509.00 19,646.00
      Shareholders Funds 13,127.00 12,468.00 14,960.00 14,854.00 18,490.00 19,627.00
      Minority Interests 1,577.00 1,681.00 1,815.00 1,908.00 18.00 17.00
      Total Equity 14,596.00 14,044.00 16,642.00 16,669.00 18,509.00 19,646.00

      Outlook

      Broker View
      Data shown is based on the past 75 days of broker views.

      ActionBrokers

      Strong Buy18

      Buy2

      Neutral3

      Sell0

      Strong Sell1

      Brokers 18 2 3 0 1
      Consensus

      ConsensusStrong Buy

      Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

      Forecasts

      Year 2020 2021 2022
      Revenue £19,423.90mn £22,286.70mn £25,203.60mn
      Pre-tax-Profit £4,899.92mn £6,302.08mn £7,874.26mn
      EPS £3.10p £3.85p £4.78p
      EPS Growth 306.76% 24.36% 23.98%
      P/E 24.39 19.61 15.82
      PEG Ratio 0.08 0.80 0.66
      Dividend 207.24p 209.71p 214.71p
      Yield 2.77% 2.81% 2.87%

      Upgrades & Downgrades (Latest 10)

      DateBrokerRecommendationPriceOld TargetNew TargetChange
      14th Jan 2021BarclaysReiteration7559p0p0pOverweight
      6th Jan 2021Shore CapitalReiteration7512p0p0pHold
      17th Dec 2020Liberum CapitalReiteration7542p9770p9430pBuy
      14th Dec 2020CitigroupReiteration7692p0p100pBuy
      27th Nov 2020CitigroupReiteration7770p0p0pBuy
      23rd Nov 2020Morgan StanleyReiteration8000p9000p9400pEqual-weight
      19th Nov 2020Berenberg BankReiteration8125p0p105pBuy
      17th Nov 2020Shore CapitalReiteration8291p0p0pHold
      17th Nov 2020JefferiesReiteration8291p0p8100pBuy
      3rd Nov 2020JP Morgan CazenoveReiteration7963p0p9500pOverweight

      Time & Sales

      All prices are in GBX and times are in GMT. Last 20 trades shown.

      Date Time Price Volume Type
      15 Jan 2021 15:32 7,551 34 Sell
      15 Jan 2021 15:32 7,551 100 Sell
      15 Jan 2021 15:32 7,551 55 Sell
      15 Jan 2021 15:32 7,552 29 Sell
      15 Jan 2021 15:32 7,552 51 Sell
      15 Jan 2021 15:32 7,552 56 Sell
      15 Jan 2021 15:32 7,551 106 Sell
      15 Jan 2021 15:32 7,552.83 65 Sell
      15 Jan 2021 15:32 7,552 50 Buy
      15 Jan 2021 15:32 7,552 75 Sell
      15 Jan 2021 15:32 7,552 57 Sell
      15 Jan 2021 15:32 7,553 30 Buy
      15 Jan 2021 15:32 7,552 36 Buy
      15 Jan 2021 15:32 7,552 14 Buy
      15 Jan 2021 15:32 7,552 3 Buy
      15 Jan 2021 15:32 7,552 36 Buy
      15 Jan 2021 15:32 7,552 200 Buy
      15 Jan 2021 15:32 7,552 22 Sell
      15 Jan 2021 15:32 7,551 52 Sell
      15 Jan 2021 15:32 7,551 40 Sell

      Selected data supplied by Thomson Reuters ©  View restrictions.

      VIEW ALL MARKET NEWS

      Investment involves risk. You may get back less than invested.